- Open Access
Potential Role of Acacia Senegal (Gum Arabic) as Immunomodulatory Agent among newly diagnosed COVID 19 Patients: A structured summary of a protocol for a randomised, controlled, clinical trial
Trials volume 21, Article number: 766 (2020)
To investigate the potential efficacy of Acacia Senegal extract Gum Arabic (GA) supplementation as immunomodulatory and anti-inflammatory dietary intervention among newly diagnosed COVID 19 Sudanese patients. To study the effect of GA on the level of cytokines, TNFα, IL8, IL6 IL10, CRP and the viral load.
Secondary outcomes will be the effect of GA oral intake on mortality rate and days of hospital admission.
Quadruple blind, randomized placebo-controlled clinical trial Phase II & III.
Prospective, two-arm, parallel-group, randomised (1:1 allocation ratio) superiority trial of oral GA among seropositive COVID-19 patients.
COVID-19 infected (newly diagnosed) as proved by real-time PCR within 72 hours of PCR.
Age 8-90 years
Intubated patients on parenteral treatment
Allergy to Gum Arabic
The study will be conducted in COVID Isolation Centres and Soba University Hospital Khartoum State Sudan.
Intervention and comparator
Experimental: Intervention Group
This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose once daily for four weeks
Placebo Comparator: Control group: This group will be provided with pectin powder provided as one-gram-dose once daily for four weeks
Both GA and placebo will be in addition to standard care treatment based on local clinical guidelines.
Mean change from baseline score of Immune Response to end of the trial. Changes of the level of Tumor Necrosis Factor (TNFα), interleukin IL8, IL6, and IL10 from the baseline values (Four weeks from the start of randomization).
Mortality rate: The percentage of deaths among COVID 19 patients received Gum Arabic compared to placebo (Four weeks from the start of randomization]).
Randomization (1:1 allocation ratio) and will be conducted using a sequence of computer-generated random numbers by an independent individual.
Each participating centre will be assigned a special code generated by the computer. The randomization will be kept by the PI and a research assistant.
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Numbers to be randomised (sample size)
110 eligible patients will be randomly assigned to either GA (n=55) or placebo (n=55) groups.
Protocol Version no 2, 30th June 2020. Recruitment will start on 15th September 2020. The intended completion date is 15th January 2021.
ClinicalTrials.gov Identifier: NCT04381871. Date of trial registration: 11 May 2020.
The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
Availability of data and materials
The datasets used and/or analysed during the current study will be available from the corresponding author on reasonable request
We would like to thank Dar Savanna Ltd. Khartoum, Sudan (www.naturegums.com) for providing gum Arabic as a gift for the study, with no future role or intervention in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. We would like to acknowledge Dr. Nashwa Eassa Dean of Scientific Deanship Alneelain University for the logistic support throughout the study.
This research is funded by a grant from Higher Education and Scientific Research Ministry in Sudan to LK and ME
Ethics approval and consent to participate
The study was approved by the Central Institutional Review Board at Al -Neelain University 23rd April 2020 (NUM-IRP-20-09-04-1). We confirm that this trial has received ethical approval from the appropriate ethical committee described above. Written informed consent will be obtained from each participant prior to enrolment or from the legal guardian for patients aged less than 18 years old.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kaddam, L., Babiker, R., Ali, S. et al. Potential Role of Acacia Senegal (Gum Arabic) as Immunomodulatory Agent among newly diagnosed COVID 19 Patients: A structured summary of a protocol for a randomised, controlled, clinical trial. Trials 21, 766 (2020). https://doi.org/10.1186/s13063-020-04707-2
- Randomised controlled trial
- Gum Arabic